Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
An estimated one-third of the world population is latently infected with Mycobacterium tuberculosis. These nonreplicating, dormant bacilli are tolerant to conventional anti-tuberculosis drugs, such as isoniazid. We recently identified diarylquinoline R207910 (also called TMC207) as an inhibitor of ATP synthase with a remarkable activity against replicating mycobacteria. In the present study, we show that R207910 kills dormant bacilli as effectively as aerobically grown bacilli with the same target specificity. Despite a transcriptional down-regulation of the ATP synthase operon and significantly lower cellular ATP levels, we show that dormant mycobacteria do possess residual ATP synthase enzymatic activity. This activity is blocked by nanomolar concentrations of R207910, thereby further reducing ATP levels and causing a pronounced bactericidal effect. We conclude that this residual ATP synthase activity is indispensable for the survival of dormant mycobacteria, making it a promising drug target to tackle dormant infections. The unique dual bactericidal activity of diarylquinolines on dormant as well as replicating bacterial subpopulations distinguishes them entirely from the current anti-tuberculosis drugs and underlines the potential of R207910 to shorten tuberculosis treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIGURE 4 ATP synthase is functional in dormant M. smegmatis . A , ATP synthesis activity in inverted membrane vesicles (50 𝛍 g/ml) from dormant M. smegmatis cultured for 10 days under Wayne O 2 depletion conditions. Positive control was membrane vesicles with buffer containing ADP, P i , and NADH, whereas negative control excluded NADH and Pi from the assay buffer. B , effect of R207910 on membrane potential in dormant M. smegmatis cultured for 10 days under Wayne O 2 depletion conditions. The membrane potential was measured using tetra-[ 3 H]phenylphosphonium bromide.](https://figures.cochat.ai/paper-figures/b01e7891765241e4a7d71c59f242a243/diarylquinolines-are-bactericidal-for-dormant-mycobacteria-as-a-result-of-figure-4.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationTranscriptional Adaptation of Mycobacterium tuberculosis within Macrophages
Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030846 · Cited by 1,420
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program
Voskuil, M. I., Schnappinger, D., Visconti, K. C., Harrell, M. I., Dolganov, G. M., Sherman, D. R., & Schoolnik, G. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030205 · Cited by 966
Muñoz-Elías, E. J., & McKinney, J. D. (2005) · Nature Medicine · doi:10.1038/nm1252 · Cited by 756
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Self-citationM. tuberculosis persistence, latency, and drug tolerance
Gomez, J. E., & McKinney, J. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.08.003 · Cited by 533
Cited by
Items 101–200 of 409
Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery
Iqbal, I., Bajeli, S., Akela, A. K., & Kumar, A. (2018) · Pathogens · doi:10.3390/pathogens7010024 · Cited by 68
“The drug is posited to be more effective against non-replicating bacteria than those that are actively replicating; this could be due to 5–10-fold lower ATP levels in the non-replicating dormant bacteria [154].”
BackgroundSAR analysis of new anti-TB drugs currently in pre-clinical and clinical development
Poce, G., Cocozza, M., Consalvi, S., & Biava, M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.066 · Cited by 66
Unpacking the Pathogen Box—An Open Source Tool for Fighting Neglected Tropical Disease
Veale, C. G. L. (2019) · ChemMedChem · doi:10.1002/cmdc.201800755 · Cited by 66
Wang, Z., Soni, V., Marriner, G. A., Kaneko, T., Boshoff, H. I., Barry, C. E., & Rhee, K. Y. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907946116 · Cited by 66
ATP synthase superassemblies in animals and plants: Two or more are better
Seelert, H., & Dencher, N. A. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.05.023 · Cited by 65
Hotra, A., Suter, M. A., Biuković, G., Ragunathan, P., Kundu, S., Dick, T., & Grüber, G. (2016) · FEBS Journal · doi:10.1111/febs.13715 · Cited by 65
Mycobacterial tuberculosis Enzyme Targets and their Inhibitors
Saxena, A. K., & Singh, A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190219105722 · Cited by 64
Lü, P., Haagsma, A. C., Pham, H. L., Maaskant, J. J., Mol, S., Lill, H., & Bald, D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00507-11 · Cited by 63
“Finally, in similarity to our data reported here for POA, TMC207 reduces cellular ATP levels (17, 18, 26).”
BackgroundSelf-citationLohrasbi, V., Talebi, M., Bialvaei, A. Z., Fattorini, L., Drancourt, M., Heidary, M., & Darban‐Sarokhalil, D. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.12.002 · Cited by 63
“generates ATP from proton translocation, and inhibition of ATP biosynthesis has been shown to kill both actively dividing and nondividing bacteria [79].”
BackgroundHatami, H., Sotgiu, G., Bostanghadiri, N., Abadi, S. S. D., Mesgarpour, B., Goudarzi, H., Migliori, G. B., & Nasiri, M. J. (2022) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210384 · Cited by 62
“(6) Bedaquiline, a diarylquinoline that inhibits mycobacterial ATP synthase, is the first antituberculosis drug in 40 years to be approved for MDR-TB patients.(7-9) The 2018 WHO guidelines recommend bedaquiline as the first drug in an all-oral regimen designed to maximize treatment outcomes while minimizing the toxici…”
BackgroundMolecular Basis of Drug Resistance in Mycobacterium tuberculosis
Cohen, K. A., Bishai, W. R., & Pym, A. S. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0036-2013 · Cited by 61
“AtpE forms a part of the F 1 F 0 proton ATP synthase, a transmembrane protein complex that generates ATP from proton translocation, and inhibition of ATP biosynthesis has been shown to kill both actively dividing and nondividing bacteria (128).”
BackgroundFoo, C. S.-Y., Pethe, K., & Lupien, A. (2020) · Applied Sciences · doi:10.3390/app10072339 · Cited by 61
“Briefly, BDQ binds to the c-subunit and the ε-subunit of the ATP synthase by mimicking key residues in the proton transfer chain and blocking the rotary movement of the c-subunit during the catalysis of ATP [165,166], disrupting a fundamental process for bacterial survival in both actively growing and non-growing stat…”
BackgroundBioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis
Hasenoehrl, E., Wiggins, T. J., & Berney, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.611683 · Cited by 61
Haydel, S. E. (2010) · Pharmaceuticals · doi:10.3390/ph3072268 · Cited by 60
Koch-Koerfges, A., Kabus, A., Ochrombel, I., Marin, K., & Bott, M. H. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.10.006 · Cited by 59
Angula, K. T., Legoabe, L. J., & Beteck, R. M. (2021) · Pharmaceuticals · doi:10.3390/ph14050461 · Cited by 59
“Notably, BDQ exhibits dual mechanisms of action that specifically target ATP synthase by inhibiting the proton pumping mechanism through binding to the oligomeric (c) and proteolipid E subunits of ATP synthase [22,55,56].”
BackgroundShah, N. B., Hutcheon, M. L., Haarer, B. K., & Duncan, T. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.451583 · Cited by 58
Mascolo, L., & Bald, D. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.11.002 · Cited by 58
Self-citationZhou, S., Wang, W., Zhou, X., Zhang, Y., Lai, Y., Tang, Y., Xu, J., Li, D., Lin, J., Yang, X., et al. (2021) · eLife · doi:10.7554/elife.69418 · Cited by 57
“Maintenance of PMF and ATP homeostasis is required for the survival of both replicative and non-replicative (often referred to as dormant) mycobacteria, and its dissipation leads to a rapid loss of cell viability and cell death ( Koul et al., 2008 ; Rao et al., 2008 ).”
New Drugs and Treatment Regimens
Sloan, D. J., Davies, G., & Khoo, S. (2013) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x113099990017 · Cited by 56
“It can be administered orally, is bactericidal against rapidly growing and metabolically quiescent organisms and is effective against DS and DR-TB [60-62].”
BackgroundHong, W. D., Gibbons, P. D., Leung, S. C., Amewu, R. K., Stocks, P. A., Stachulski, A. V., Horta, P., Cristiano, M. L. S., Shone, A. E., Moss, D. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01718 · Cited by 55
“Targeting components of the Mtb respiratory chain (Figure 2) has been shown by us and other laboratories, to be effective in sterilizing both replicating and dormant Mtb.(9-18) The initial target”
InfluentialChallenges in the development of drugs for the treatment of tuberculosis
Shehzad, A., Rehman, G., Ul‐Islam, M., Khattak, W. A., & Lee, Y. S. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.10.009 · Cited by 55
Pruksakorn, P., Arai, M., Liu, L., Moodley, P., Jacobs, W. R., & Kobayashi, M. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1287 · Cited by 55
TARGETING DORMANT BACILLI TO FIGHT TUBERCULOSIS
Fattorini, L., Piccaro, G., Mustazzolu, A., & Giannoni, F. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.072 · Cited by 54
Alderwick, L. J., Lloyd, G. S., Lloyd, A. J., Lovering, A. L., Eggeling, L., & Besra, G. S. (2010) · Glycobiology · doi:10.1093/glycob/cwq173 · Cited by 52
“However, these “dormant” TB bacilli still require a basal level of “energy” metabolites in order to maintain critical cellular functions (Koul et al. 2008).”
BackgroundTranscriptomic changes of Legionella pneumophila in water
Li, L., Mendis, N., Trigui, H., & Faucher, S. P. (2015) · BMC Genomics · doi:10.1186/s12864-015-1869-6 · Cited by 52
“This suggests a lower level of energy metabolism and thus, reduced metabolic activity in Lp, as the down-regulation of ATP synthase is usually found in dormant bacteria with a lower cellular ATP level [59].”
BackgroundKalia, N. P., Singh, S., Hards, K., Cheung, C., Sviriaeva, E. N., Banaei‐Esfahani, A., Aebersold, R. H., Berney, M., Cook, G. M., & Pethe, K. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112444 · Cited by 51
Tuberculosis drug discovery and emerging targets
Mdluli, K. E., Kaneko, T., & Upton, A. M. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12459 · Cited by 51
New treatment options for multidrug-resistant tuberculosis
Field, S. K., Fisher, D., Jarand, J. M., & Cowie, R. L. (2012) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465812452193 · Cited by 49
“Diarylquinolines reduce adenosine triphosphate (ATP) levels by selectively inhibiting mycobacterial ATP synthase but have little effect on other bacteria and virtually none on the homologous enzyme in eukaryotes [Andries et al. 2005; Haagsma et al. 2009, 2011; Koul et al. 2007, Koul et al. 2008].”
BackgroundTuberculosis Drugs: New Candidates and How to Find More
Sala, C., & Hartkoorn, R. C. (2011) · Future Microbiology · doi:10.2217/fmb.11.46 · Cited by 48
Hards, K., Cheung, C., Waller, N. J. E., Adolph, C., Keighley, L. M., Tee, Z. S., Harold, L. K., Menorca, A., Bujaroski, R. S., Buckley, B. J., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03110-8 · Cited by 48
Understanding the contribution of metabolism to Mycobacterium tuberculosis drug tolerance
Samuels, A. N., Wang, E. R., Harrison, G. A., Valenta, J. C., & Stallings, C. L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.958555 · Cited by 47
Berube, B. J., & Parish, T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01677-17 · Cited by 47
“As expected from an agent with activity against nonreplicating bacteria (6), we saw a time-dependent decrease in bacterial viability for all three strains treated with BDQ (Fig.”
BackgroundBambeke, F. V., Mingeot‐Leclercq, M., Glupczynski, Y., & Tulkens, P. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00137-4 · Cited by 48
Cambré, A., & Aertsen, A. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00008-20 · Cited by 46
F1·Fo ATP Synthase/ATPase: Contemporary View on Unidirectional Catalysis
Zharova, T. V., Grivennikova, V. G., & Borisov, V. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065417 · Cited by 45
“ATP production and a substantial decrease in ATP levels [119,121].”
BackgroundBerube, B. J., Russell, D., Castro, L., Choi, S., Narayanasamy, P., & Parish, T. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02661-18 · Cited by 43
“tuberculosis during active disease and also for the maintenance of basal metabolic activity during latent infection (5, 6).”
BackgroundFighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli
Fattorini, L., Iacobino, A., Piccaro, G., Giannoni, F., & Mustazzolu, A. (2017) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_85_17 · Cited by 43
Mazloum, N. A., Stegman, M. A., Croteau, D. L., Houten, B. V., Kwon, N. S., Ling, Y., Dickinson, C. E., Venugopal, A., Towheed, M. A., & Nathan, C. (2011) · Biochemistry · doi:10.1021/bi101674c · Cited by 43
“1:2:3 (Supporting Information Figure S2), at a physiologic concentration of ATP (1-5 mM) (32) (Supporting Information”
Nguyen, T. V. A., Cao, T. B. T., Akkerman, O. W., Tiberi, S., Vu, D. H., & Alffenaar, J. W. C. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1200462 · Cited by 42
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae
Wang, X., Zeng, Y., Li, S., Larson, P. G., Liu, X., Zou, X., Wang, S., Guo, K., Ma, C., Zhang, G., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01353 · Cited by 42
Lessons from Seven Decades of Antituberculosis Drug Discovery
Barry, C. E. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795429158 · Cited by 42
“The fundamental biology of Mycobacterium tuberculosis (Mtb) has advanced extraordinarily in the same time period, in some ways to such an extent that TB has now become a model organism for the development and application of new tools in genomics and systems biology.”
BackgroundInfluentialInhibitors of ATP Synthase as New Antibacterial Candidates
Mackieh, R., Al-Bakkar, N., Kfoury, M., Roufayel, R., Sabatier, J., & Fajloun, Z. (2023) · Antibiotics · doi:10.3390/antibiotics12040650 · Cited by 41
New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
Leibert, E. M., Rom, W. N., & DANCKERS, M. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s37743 · Cited by 41
“This property could potentially allow for shorter treatment durations.(27,38)”
Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase
Khan, S. R., Singh, S., Roy, K. K., Akhtar, M. S., Saxena, A. K., & Krishnan, M. Y. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.09.012 · Cited by 41
Roles of the two type II NADH dehydrogenases in the survival of Mycobacterium tuberculosis in vitro
Awasthy, D., Ambady, A., Narayana, A., Morayya, S., & Sharma, U. K. (2014) · Gene · doi:10.1016/j.gene.2014.08.024 · Cited by 40
“Elucidation of mechanism of action of the recently discovered anti-TB drug Bedaquiline (TMC-207) has shown that ATP generation by ATP synthase in oxidative phosphorylation pathway is an essential process in Mtb (Koul et al., 2008).”
BackgroundTargeting the cytochrome oxidases for drug development in mycobacteria
Lee, B. S., Sviriaeva, E. N., & Pethe, K. (2020) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2020.02.001 · Cited by 41
Sellamuthu, S., Singh, M., Kumar, A., & Singh, S. K. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1327577 · Cited by 40
The Mycobacterium tuberculosis genome at 25 years: lessons and lingering questions
Koleske, B. N., Jacobs, W. R., & Bishai, W. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci173156 · Cited by 39
“1172/JCI173156 suggested that the compound could kill even dormant bacteria (90, 91).”
BackgroundBedaquiline: A Novel Antitubercular Agent for the Treatment of Multidrug- Resistant Tuberculosis
Yadav, S., Rawal, G., & Baxi, M. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/19052.8286 · Cited by 39
“It inhibits both actively replicating and non-replicating mycobacteria, with one study showing inhibition of dormant cells in latent TB infection at a low concentration [11].”
BackgroundInfluentialGELBER, R. H., Andries, K., Paredes, R. M. D., Andaya, C. E. S., & Burgos, J. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00722-09 · Cited by 38
“berculosis bacilli (15), and herein we have demonstrated with”
BackgroundSelf-citation2-aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain
Jeon, A. B., Ackart, D. F., Li, W., Jackson, M., Melander, R. J., Melander, C., Abramovitch, R. B., Chicco, A. J., Basaraba, R. J., & Obregón‐Henao, A. (2019) · Scientific Reports · doi:10.1038/s41598-018-38064-7 · Cited by 37
Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis
Makarov, V., Salina, E. G., Reynolds, R. C., Zin, P. P. K., & Ekins, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02075 · Cited by 37
“104 MOLECULAR DIVERSITY OF RECENT COMPOUNDS FOR TB Interestingly, only a relatively small number (17) of the 118 molecules in Tables 3–12 (representing 14%) are Pan Assay Interference compounds (PAINS) as assessed using the FAF-3 online software105.”
MethodSmall organic molecules targeting the energy metabolism of Mycobacterium tuberculosis
Urban, M., Šlachtová, V., & Brulíková, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113139 · Cited by 37
Molecular Mechanisms of MmpL3 Function and Inhibition
Williams, J. T., & Abramovitch, R. B. (2023) · Microbial Drug Resistance · doi:10.1089/mdr.2021.0424 · Cited by 36
Jeffreys, L. N., Ardrey, A., Hafiz, T. A., Dyer, L.-A., Warman, A. J., Mosallam, N., Nixon, G. L., Fisher, N. E., Hong, W. D., Leung, S. C., et al. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00283 · Cited by 35
Triazaspirodimethoxybenzoyls as Selective Inhibitors of Mycobacterial Lipoamide Dehydrogenase,
Bryk, R., Arango, N., Venugopal, A., Warren, J. D., Park, Y., Patel, M. S., Lima, C. D., & Nathan, C. (2010) · Biochemistry · doi:10.1021/bi9016186 · Cited by 35
“This agent is active against both replicating and non-replicating Mtb, suggesting that energy production pathways can be effective targets in elimination of non-replicators (10).”
BackgroundThe Spectrum of Drug Susceptibility in Mycobacteria
Aldridge, B. B., Keren, I., & Fortune, S. M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0031-2013 · Cited by 33
“…targeting ATP synthesis, which have increased activity against dormant mycobacteria (generated through hypoxia) as compared to actively growing cells (12), and drugs that target the altered metabolic state speci fi cally, such as metronidazole, which is active only under hypoxic conditions (13, 14).”
BackgroundR207910 (TMC207) : un nouvel antibiotique pour le traitement de la tuberculose
Lounis, N., Guillemont, J., Véziris, N., Koul, A., Jarlier, V., & Andries, K. (2009) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.09.007 · Cited by 33
Self-citationAdolph, C., McNeil, M. B., & Cook, G. M. (2022) · mBio · doi:10.1128/mbio.01672-22 · Cited by 32
Experimental Models Used to Study Human Tuberculosis
O’Toole, R. (2010) · Advances in applied microbiology · doi:10.1016/s0065-2164(10)71003-0 · Cited by 32
Ofori-Anyinam, B., Hamblin, M., Coldren, M. L., Li, B., Mereddy, G., Shaikh, M., Shah, A., Grady, C. A., Ranu, N., Lu, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53933-8 · Cited by 30
Targeting mycobacterial membranes and membrane proteins: Progress and limitations
Kumar, G., & Kapoor, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117212 · Cited by 30
Winter, H. R., Egizi, E., Murray, S. R., Erondu, N., Ginsberg, A. M., Rouse, D. J., Severynse-Stevens, D., & Pauli, E. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04171-14 · Cited by 30
“tuberculosis isolates (4, 5) and is also bactericidal against nonreplicating tubercle bacilli (6).”
BackgroundBald, D., & Koul, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.09.007 · Cited by 30
Self-citationSilva, C. D. M., Hajihosseini, A., Myrick, J., Nole, J., Louie, A., Schmidt, S., & Drusano, G. L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00856-18 · Cited by 30
Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures
Batyrshina, Y., & Schwartz, Y. S. (2019) · Tuberculosis · doi:10.1016/j.tube.2019.05.005 · Cited by 29
Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis
Goel, D. (2014) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.124435 · Cited by 29
“This compound has shown high activity against both sensitive as well as resistant strain of mycobacterium.[8] ATP synthetase is the essential enzyme for the production for energy in the all‐living organisms.”
BackgroundNath, S. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10106 · Cited by 29
“and this ATP depletion may be a determinant of the observed delayed onset of killing.(19) However, mycobacterial cells can be depleted of”
BackgroundBedaquiline and Delamanid for Drug-Resistant Tuberculosis: A Clinician’s Perspective
Guglielmetti, L., Chiesi, S., Eimer, J., Domínguez, J., Masini, T., Varaine, F., Véziris, N., Ader, F., & Robert, J. (2020) · Future Microbiology · doi:10.2217/fmb-2019-0309 · Cited by 29
The Medicinal Chemistry of Tuberculosis Chemotherapy
Marriner, G. A., Nayyar, A., Uh, E., Wong, S. Y., Mukherjee, T., Via, L. E., Carroll, M., Edwards, R. L., Gruber, T. D., Choi, I., et al. (2011) · Topics in medicinal chemistry · doi:10.1007/7355_2011_13 · Cited by 29
“Furthermore, TMC207 has also been shown to be bactericidal in vitro against non-replicating MTb, suggesting that TMC207 might prove therapeutically effective against latent tuberculosis [180].”
BackgroundIdentification and synthesis of novel inhibitors of mycobacterium ATP synthase
Surase, Y. B., Samby, K., Amale, S. R., Sood, R., Purnapatre, K. P., Pareek, P. K., Das, B., Nanda, K., Kumar, S., & Verma, A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.081 · Cited by 29
Denny, W. A., & Palmer, B. D. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.207 · Cited by 28
Snášel, J., Nauš, P., Dostál, J., Hnízda, A., Fanfrlík, J., Brynda, J., Bourderioux, A., Dušek, M., Dvořáková, H., Stolaříková, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500497v · Cited by 28
Filling the Pipeline - New Drugs for an Old Disease
Stehr, M., Elamin, A. A., & Singh, M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026613666131113152908 · Cited by 28
“tuberculosis [30,31].”
Lawer, A., Tyler, C., Hards, K., Keighley, L. M., Cheung, C., Kierek, F., Su, S., Matikonda, S. S., McInnes, T., Tyndall, J. D. A., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00401 · Cited by 27
de Keijzer, J., Mulder, A., de Beer, J., de Ru, A. H., van Veelen, P. A., & van Soolingen, D. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01073 · Cited by 27
Laohapojanart, N., Ratanajamit, C., Kawkitinarong, K., & Srichana, T. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102056 · Cited by 26
Hu, Y., Pertinez, H. E., Liu, Y., Davies, G., & Coates, A. R. M. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz052 · Cited by 26
Effect of bedaquiline on the functions of rat liver mitochondria
Belosludtsev, K. N., Belosludtseva, N. V., Talanov, E. Y., Tenkov, K. S., Starinets, V. S., Agafonov, A. V., Pavlik, L. L., & Dubinin, M. V. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.06.012 · Cited by 25
Polyphosphate Kinase from M. tuberculosis: An Interconnect between the Genetic and Biochemical Role
Jagannathan, V., Kaur, P., & Datta, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014336 · Cited by 25
Novel treatments in multidrug-resistant tuberculosis
Mondoni, M., Saderi, L., & Sotgiu, G. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.05.007 · Cited by 24
Muronetz, V. I., Melnikova, A. K., Barinova, K. V., & Schmalhausen, E. V. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919110051 · Cited by 24
New drugs and regimens for treatment of TB
Leibert, E. M., & Rom, W. N. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.60 · Cited by 24
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T. E., & Berney, M. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch20 · Cited by 24
New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053
Chiarelli, L. R., Salina, E. G., Mori, G., Azhikina, T. L., Riabova, O., Lepioshkin, A., Grigorov, A., Forbak, M., Madacki, J., Orena, B. S., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00388 · Cited by 23
Binding properties of the anti-TB drugs bedaquiline and TBAJ-876 to a mycobacterial F-ATP synthase
Krah, A., Grüber, G., & Bond, P. J. (2022) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2022.09.001 · Cited by 23
In Vitro Model of Mycobacterial Growth Arrest Using Nitric Oxide with Limited Air
Hussain, S., Malik, M., Shi, L., Gennaro, M. L., & Drlica, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00442-08 · Cited by 21
“It will now be interesting to examine new compounds, such as diarylquinolines, for lethal activity with the DETA-NO-mediated growth arrest system described above, since one of the diarylquinolines shows excellent activity with several dormancy models (5).”
BackgroundAdolph, C., Cheung, C., McNeil, M. B., Jowsey, W. J., Williams, Z. C., Hards, K., Harold, L. K., Aboelela, A., Bujaroski, R. S., Buckley, B. J., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.12.002 · Cited by 21
Zhou, W., & Faraldo‐Gómez, J. D. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.03.019 · Cited by 21
Egorova, A., Salina, E. G., & Makarov, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413317 · Cited by 21
Metabolic Perspectives on Persistence
Hartman, T. E., Wang, Z., Jansen, R. S., Gardete, S., & Rhee, K. Y. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0026-2016 · Cited by 21
Gray, W. A., Waldorf, B., Rao, M. G., Stiles, B. L., Griffiss, J. M., Salata, R. A., & Blumer, J. L. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.07.023 · Cited by 20
Are all antibiotic persisters created equal?
Shultis, M. W., Mulholland, C. V., & Berney, M. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.933458 · Cited by 19
“Two of these drugs, bedaquiline and delamanid, have demonstrated activity against dormant bacteria (Koul et al., 2008; Chen et al., 2017).”
BackgroundA quantitative analysis of ligand binding at the protein-lipid bilayer interface
Barkdull, A. P., Holcomb, M., & Forli, S. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01472-8 · Cited by 19
“Cytochrome bcc complexes are important for mycobacterial survival as they establish a proton gradient essential for adenosine triphosphate (ATP) synthesis 76 .”
Genetics and roadblocks of drug resistant tuberculosis
Perdigão, J., & Portugal, I. (2018) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2018.09.023 · Cited by 19
Tuberculosis: current scenario, drug targets, and future prospects
Bose, P., Harit, A. K., Das, R., Sau, S., Iyer, A. K., & Kashaw, S. K. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02691-5 · Cited by 19
An update on ATP synthase inhibitors: A unique target for drug development in M. tuberculosis
Kelam, L. M., Wani, M. A., & Dhaked, D. K. (2023) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2023.04.009 · Cited by 19
Bedaquiline: A novel antitubercular drug for multidrug-resistant tuberculosis
Nagabushan, H., & Roopadevi, H. S. (2014) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.138772 · Cited by 19
Rastogi, S., Singh, A. K., Chandra, G., Kushwaha, P., Pant, G., Singh, K., Mitra, K., Sashidhara, K. V., & Krishnan, M. Y. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.02.001 · Cited by 19
Metadata
- Authors
- Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Göhlmann, H. W. H., Willebrords, R., Poncelet, A., Guillemont, J., Bald, D., & Andries, K.
- Affiliations
- Johnson & Johnson (France) (FR)
- Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Koul, Anil
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 283
- Issue
- 37
- Pages
- 25273-25280
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2164282552
- Cited by
- 364
- References
- 31
- Citations by year
- 2026: 16 · 2025: 17 · 2024: 10 · 2023: 19 · 2022: 16 · 2021: 22 · 2020: 23 · 2019: 25 · 2018: 17 · 2017: 25 · 2016: 15 · 2015: 20 · 2014: 29 · 2013: 20 · 2012: 22
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4495 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- diarylquinolines, bedaquiline, Mycobacterium tuberculosis, dormant mycobacteria, latent tuberculosis infection, ATP synthase inhibition, ATP homeostasis, bactericidal activity, tuberculosis drug targets
- MeSH terms
- Adenosine Triphosphate, Antitubercular Agents, Homeostasis, Models, Biological, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Nitric Oxide, Oxygen, Quinolines, RNA, Messenger, Time Factors, Gene Expression Regulation, Bacterial, Mycobacterium smegmatis, Mitochondrial Proton-Translocating ATPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.